3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
4
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
3
Thrombocytosis
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Blast Crisis
1
Anemia
1
Interventions
enzalutamide
4
abiraterone
2
Docetaxel
2
tasquinimod
1
sabizabulin
1
olaparib
1
ipatasertib
1
darolutamide
1
atezolizumab
1
Nivolumab
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Prostatic Neoplasms, Castration-Resistant
×
darolutamide
×
Clear all
NCT04157088
2023-08-04
DaroAcT
Bayer
Phase 2
Terminated
30 enrolled
25 charts